The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design

BACKGROUND: Randomized controlled trials showed the nonvitamin K oral anticoagulant (NOAC) edoxaban was effective and safe for stroke and systemic embolism prevention in nonvalvular atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolism (VTE; including pulmonary embo...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cardiol
Main Authors: De Caterina, Raffaele, Agnelli, Giancarlo, Laeis, Petra, Unverdorben, Martin, Rauer, Heiko, Wang, Chun‐Chieh, Nakamura, Mashio, Chiu, Kuan‐Ming, Reimitz, Paul‐Egbert, Koretsune, Yukihiro, Chen, Cathy, Thee, Ulrike, Kaburagi, Jumpei, Kim, Young‐Hoon, Choi, Won‐Il, Yamashita, Takeshi, Cohen, Alexander, Kirchhof, Paulus
Format: Artigo
Language:Inglês
Published: Wiley Periodicals, Inc. 2019
Subjects:
Trial Designs
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906985/
https://ncbi.nlm.nih.gov/pubmed/31650560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23279
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items